ArticleSmall (Weinheim an der Bergstrasse, Germany)2026
Bioengineered Bacterial Vesicles and Biomimetic Hybrids Eliminate Biofilms and Balance the Gut Microbiome.
Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Probiotics and Extracellular Vesicles as Redox Modulators in Wound Healing: From Microbial Therapeutics to Engineered Nanotherapeutic Strategies.Antioxidants (Basel, Switzerland) · 2026Review
- Engineered bacterial extracellular vesicles as next-generation precision postbiotics: strategies, challenges and prospects.Extracellular vesicles and circulating nucleic acids · 2026Review
- Liposome drug delivery strategies: state-of-the-art for combating bacterial biofilms.Frontiers in microbiology · 2026Review
- Bacterial extracellular vesicles as multifaceted regulators of human diseases and emerging therapeutic platforms.Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Antibiotic-resistant pathogens are a global health challenge, necessitating innovative solutions beyond conventional antibiotics. This study introduces biomimetic nanocarriers - hybrids of bacteriomimetic liposomes and biocompatible Myxobacteria outer-membrane vesicles (OMVs) - as tunable platforms for targeted antibiotic delivery. Comparative analyses of their physicochemical properties and interactions with immune cells, intestinal epithelium, and biofilm-forming pathogens reveal distinct advantages. Hybrids excel at delivering antibiotics to intracellular targets, while Myxobacteria OMVs, particularly those of strain SBSr 073, evade immune clearance and prolong extracellular drug exposure. To support clinical translation, this study optimizes antibiotic encapsulation methods for SBSr 073 OMVs and evaluates the short- and long-term impact of Cystobacter ferrugineus 23 strain OMVs on the gut microbiome in mice. Summing up, this study highlights the promise of Myxobacteria OMVs and their biomimetic hybrids as versatile tools for treating Gram-negative biofilm-forming pathogens. These findings underscore the potential of bioengineered and biomimetic drug carriers for combating antimicrobial resistance and pave the way for their translation toward difficult-to-treat infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.